Company Overview of Sunovion Pharmaceuticals Inc.
Sunovion Pharmaceuticals Inc. develops and markets pharmaceutical products. The company offers products for central nervous system disorders, such as insomnia, schizophrenia, bipolar depression, and epilepsy disorders; and respiratory conditions, including asthma, allergy, and chronic obstructive pulmonary disease areas. Sunovion Pharmaceuticals Inc. was formerly known as Sepracor Inc. and changed its name to Sunovion Pharmaceuticals Inc. in October 2010. The company was founded in 1984 and is headquartered in Marlborough, Massachusetts. As of October 20, 2009, Sunovion Pharmaceuticals Inc. operates as a subsidiary of Dainippon Sumitomo Pharma America Holdings, Inc.
84 Waterford Drive
Marlborough, MA 01752
Founded in 1984
Key Executives for Sunovion Pharmaceuticals Inc.
Vice Chair, President and Head of Global Clinical Development - Sumitomo Dainippon Pharma Group
Chief Financial Officer and Senior Vice President
Chief Administrative Officer and Executive Vice President
Chief Compliance & Ethics Officer and Senior Vice President
Head of Global Business Development and Executive Vice President
Compensation as of Fiscal Year 2015.
Sunovion Pharmaceuticals Inc. Key Developments
PsychoGenics Extends its Drug Discovery Collaboration with Sunovion
Sep 14 15
PGI Drug Discovery LLC (PsychoGenics) announced that the Company has extended its drug discovery and development collaboration with Sunovion Pharmaceuticals Inc. (Sunovion) for another four years. In August 2007, PsychoGenics and Sunovion entered into a drug discovery and development agreement to combine their complementary strengths and expertise to screen compound libraries and identify a new generation of treatments for neuropsychiatric disorders. Since then the companies have expanded the scope of the collaboration, which has led to the identification of potential drug candidates including a compound in clinical development.
Sunovion Pharmaceuticals Inc Receives FDA Approval for Aptiom as Monotherapy for Partial-Onset Seizures
Aug 28 15
Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Aptiom (eslicarbazepine acetate) as monotherapy for the treatment of partial-onset seizures. This new approved indication allows APTIOM to be used as monotherapy in people who initiate treatment for the first time or convert from other antiepileptic drugs (AEDs) to APTIOM. Previously approved in 2013 by the FDA as adjunctive therapy for partial-onset seizures, APTIOM is the only exclusively once-daily non-extended release AED, which can be used alone or in combination with other AEDs in the treatment of partial-onset seizures. The approval of APTIOM as monotherapy for partial-onset seizures was supported by data from two pivotal Phase 3 clinical trials (Studies 093-045 and 093-046). Both trials met the pre-specified primary endpoint agreed upon with the FDA. Two identically designed Phase 3, dose-blinded, historical-controlled, multi-center, randomized clinical trials (Studies 093-045 and 093-046) evaluated the safety and efficacy of APTIOM (1,600 mg/day or 1,200 mg/day) as monotherapy for partial-onset seizures in patients 16 years of age or older whose seizures were not well-controlled with other antiepileptic drugs (AEDs).
Sunovion Pharmaceuticals Announces Results of Two Health Outcomes Studies and Placebo Controlled Randomized Trial
May 20 15
Sunovion Pharmaceuticals Inc. announced the results of two health outcomes studies and a placebo controlled randomized trial presented at the American Thoracic Society (ATS) 2015 Annual Meeting in Denver. Results from these studies demonstrated that a substantial proportion of hospitalized chronic obstructive pulmonary disease (COPD) patients are not provided maintenance treatments; one in three patients report low confidence in using COPD devices and a majority of these patients have low treatment adherence; and more patients on Brovana (arformoterol tartrate) Inhalation Solution reported clinically significant improvements in health-status compared with placebo. Treatment Patterns for Inpatients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (Poster Board #P620) In a retrospective analysis of claims data collected from more than 500 hospitals across the U.S. in 2012, inpatient treatment patterns for patients hospitalized with acute exacerbations of COPD indicated that 78.2% were treated with multiple bronchodilators. Only 52.5% of patients received long-acting bronchodilators while hospitalized, although the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines state that in the hospital prior to discharge, patients should start long-acting bronchodilators, either beta2-agonists and/or anticholinergics with or without inhaled corticosteroids.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|